Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 7,604 shares at $14.75 ($112K) on 2017-08-15, disclosed to the SEC on 2017-08-17.
Open-market sale of $112k ATRA by EVP, R&D & Chief Scientific Of. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ATRA | SELL | 2019-02-08 | $956K | — | Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |